valproic acid has been researched along with Acute Lymphoid Leukemia in 11 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hyperleukocytosis may be associated with an early morbidity and mortality due to leukostasis." | 5.39 | The activity of valproic Acid in the treatment of refractory hyperleukocytosis in a child with acute lymphoblastic leukemia. ( Koksal, Y; Kose, D, 2013) |
| "Although survival rates for acute lymphocytic leukemia (ALL), especially in children, have shown dramatic improvement over time, poor outcomes are still observed in patients who have refractory or relapsed disease after conventional chemotherapy." | 2.49 | Recent advancements of bortezomib in acute lymphocytic leukemia treatment. ( Chen, Q; Du, XL, 2013) |
| "Hyperleukocytosis may be associated with an early morbidity and mortality due to leukostasis." | 1.39 | The activity of valproic Acid in the treatment of refractory hyperleukocytosis in a child with acute lymphoblastic leukemia. ( Koksal, Y; Kose, D, 2013) |
| "Acute lymphoblastic leukemia (ALL) has previously been considered resistant to NK cell lysis and not tractable to this approach." | 1.39 | Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands. ( Bigley, V; Collin, M; Hambleton, S; Jardine, L; Pagan, S; Wang, XN, 2013) |
| "A particular VPA/ATRA responsiveness of Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (ALL) was confirmed in a therapy-refractory patient in vivo." | 1.33 | FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment. ( Barth, PJ; Burchert, A; Cai, D; Neubauer, A; Ottmann, OG; Wang, Y, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Harju, T | 1 |
| Hurme-Niiranen, A | 1 |
| Suo-Palosaari, M | 1 |
| Nygaard Nielsen, S | 1 |
| Hinttala, R | 1 |
| Schmiegelow, K | 1 |
| Uusimaa, J | 1 |
| Harila, A | 1 |
| Niinimäki, R | 1 |
| Rahmé, R | 1 |
| Benayoun, E | 1 |
| Pautas, C | 1 |
| Cordonnier, C | 1 |
| Wagner-Ballon, O | 1 |
| Maury, S | 1 |
| Kose, D | 1 |
| Koksal, Y | 1 |
| Kircher, B | 1 |
| Schumacher, P | 1 |
| Petzer, A | 1 |
| Hoflehner, E | 1 |
| Haun, M | 1 |
| Wolf, AM | 1 |
| Nachbaur, D | 1 |
| Gastl, G | 1 |
| Shao, N | 1 |
| Zou, J | 1 |
| Li, J | 1 |
| Chen, F | 1 |
| Dai, J | 1 |
| Qu, X | 1 |
| Sun, X | 1 |
| Ma, D | 1 |
| Ji, C | 1 |
| Jardine, L | 1 |
| Hambleton, S | 1 |
| Bigley, V | 1 |
| Pagan, S | 1 |
| Wang, XN | 1 |
| Collin, M | 1 |
| Du, XL | 1 |
| Chen, Q | 1 |
| Sun, BL | 1 |
| Wu, LH | 1 |
| Wu, YJ | 1 |
| Cai, D | 1 |
| Wang, Y | 1 |
| Ottmann, OG | 1 |
| Barth, PJ | 1 |
| Neubauer, A | 1 |
| Burchert, A | 1 |
| Helbig, I | 1 |
| Matigian, NA | 1 |
| Vadlamudi, L | 1 |
| Lawrence, KM | 1 |
| Bayly, MA | 1 |
| Bain, SM | 1 |
| Diyagama, D | 1 |
| Scheffer, IE | 1 |
| Mulley, JC | 1 |
| Holloway, AJ | 1 |
| Dibbens, LM | 1 |
| Berkovic, SF | 1 |
| Hayward, NK | 1 |
| Aiken, TC | 1 |
| Collin, RC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation Followed By Maintenance Therapy With the Novel Oral Proteasome Inhibitor, MLN9708, in Patients With High-risk Hematologic Malignancies[NCT02169791] | Phase 2 | 29 participants (Actual) | Interventional | 2014-07-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To measure CD3 donor chimerism post-transplant (NCT02169791)
Timeframe: 30 days
| Intervention | percentage of chimerism (Median) |
|---|---|
| Haploidentical Transplant | 100 |
To measure CD33 donor chimerism at Day 30 (NCT02169791)
Timeframe: 30 days
| Intervention | percentage of chimerism (Median) |
|---|---|
| Haploidentical Transplant | 100 |
To measure days to onset of acute graft versus host disease (NCT02169791)
Timeframe: 100 days
| Intervention | days (Median) |
|---|---|
| Haploidentical Transplant | 28.5 |
To obtain time to neutrophil engraftment post-transplant (NCT02169791)
Timeframe: 1 year
| Intervention | days (Median) |
|---|---|
| Haploidentical Transplant | 16 |
To estimate the incidence of relapse/progression at one-year post-transplant. (NCT02169791)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Haploidentical Transplant | 10 |
To measure the time to platelet recovery post-transplant (NCT02169791)
Timeframe: 1 year
| Intervention | days (Median) |
|---|---|
| Haploidentical Transplant | 29 |
1 review available for valproic acid and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Recent advancements of bortezomib in acute lymphocytic leukemia treatment.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Fusion Proteins, bcr-ab | 2013 |
10 other studies available for valproic acid and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
DNA polymerase gamma variants and hepatotoxicity during maintenance therapy of childhood acute lymphoblastic leukemia: is there a causal relationship?
Topics: Chemical and Drug Induced Liver Injury; DNA Polymerase gamma; Humans; Mercaptopurine; Precursor Cell | 2023 |
Treatment with 5-azacytidin upregulates the expression of CD20 in CD20-negative B cell acute lymphoblastic leukemia: a case report.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antimetabolites, Antineoplastic; Anti | 2013 |
The activity of valproic Acid in the treatment of refractory hyperleukocytosis in a child with acute lymphoblastic leukemia.
Topics: Child; Enzyme Inhibitors; Female; Humans; Leukocytosis; Precursor Cell Lymphoblastic Leukemia-Lympho | 2013 |
Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Benzamides; Case-Control Studies; Cell Line, Tumor; | 2009 |
Hyper-activation of WNT/β-catenin signaling pathway mediates anti-tumor effects of histone deacetylase inhibitors in acute T lymphoblastic leukemia.
Topics: Apoptosis; beta Catenin; Blotting, Western; Caspase 3; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell | 2012 |
Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands.
Topics: Boronic Acids; Bortezomib; Cell Degranulation; Cell Line, Tumor; Chromans; Humans; Killer Cells, Nat | 2013 |
[Effects of valproate acid combined with pirarubicin on childhood acute lymphoblastic leukemia cell line].
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Humans; Precursor Cell Lymphoblastic L | 2012 |
FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment.
Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Transformation, Neoplastic; Drug Resistance, Neopla | 2006 |
Gene expression analysis in absence epilepsy using a monozygotic twin design.
Topics: Adult; Anticonvulsants; Calcium-Binding Proteins; Cell Line, Tumor; Early Growth Response Protein 1; | 2008 |
A possible anti-emetic role for sodium valproate in cytotoxic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Drug Resistance; Epilepsy; Humans; Leukemia, Myeloid; Male; Midd | 1995 |